---
figid: PMC4279797__13023_2014_201_Fig1_HTML
figtitle: Pharmacology network-based drug repurposing for CMT1A disease
organisms:
- NA
pmcid: PMC4279797
filename: 13023_2014_201_Fig1_HTML.jpg
figlink: /pmc/articles/PMC4279797/figure/Fig1/
number: F1
caption: 'Pharmacology network-based drug repurposing for CMT1A disease. For detailed
  explanations and abbreviations, see Additional file . (A) Three principal pathways
  regulating expression of PMP22 gene through extracellular GPCR signalling in Schwann
  cells. The functional interaction between cAMP pathway, neurosteroid-mediated signalling
  and PI3K-AKT/ERK kinase cascades, activated by receptor tyrosine kinases, control
  the expression of PMP22 gene in Schwann cells. Individual drugs are shown in green.
  Blue shading: cAMP pathway; green shading: neurosteroid-mediated signalling; yellow
  shading: RTK/PI3K-AKT/ERK kinase cascades. (B) Cytoprotective and neuromodulator
  actions of PXT3003 drug combination in peripheral neurons. Dysfunction of CMT1A
  Schwann cells could affect membrane excitability of neuronal cells, leading to abnormal
  processing of neuronal information, cytotoxicity and axonal loss. GPCRs, modulated
  by PXT3003 drugs, are well-known regulators of neuronal excitability and pain sensation,
  are able to activate cytoprotective signalling pathways in different experimental
  settings, and could preserve functional integrity of peripheral neurons in CMT1
  patients. Baclofen, naltrexone and sorbitol are shown in green. Red symbols: established
  or putative functional targets for PTX3003 drugs. Blue arrows: activation links;
  red lines: inhibition links; dashed lines: functional effect link is receptor-type
  specific.'
papertitle: Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates
  Pmp22 over-expression and improves myelination, axonal and functional parameters
  in models of CMT1A neuropathy.
reftext: Ilya Chumakov, et al. Orphanet J Rare Dis. 2014;9:201.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.872434
figid_alias: PMC4279797__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4279797__F1
ndex: d033ad32-df1b-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4279797__13023_2014_201_Fig1_HTML.html
  '@type': Dataset
  description: 'Pharmacology network-based drug repurposing for CMT1A disease. For
    detailed explanations and abbreviations, see Additional file . (A) Three principal
    pathways regulating expression of PMP22 gene through extracellular GPCR signalling
    in Schwann cells. The functional interaction between cAMP pathway, neurosteroid-mediated
    signalling and PI3K-AKT/ERK kinase cascades, activated by receptor tyrosine kinases,
    control the expression of PMP22 gene in Schwann cells. Individual drugs are shown
    in green. Blue shading: cAMP pathway; green shading: neurosteroid-mediated signalling;
    yellow shading: RTK/PI3K-AKT/ERK kinase cascades. (B) Cytoprotective and neuromodulator
    actions of PXT3003 drug combination in peripheral neurons. Dysfunction of CMT1A
    Schwann cells could affect membrane excitability of neuronal cells, leading to
    abnormal processing of neuronal information, cytotoxicity and axonal loss. GPCRs,
    modulated by PXT3003 drugs, are well-known regulators of neuronal excitability
    and pain sensation, are able to activate cytoprotective signalling pathways in
    different experimental settings, and could preserve functional integrity of peripheral
    neurons in CMT1 patients. Baclofen, naltrexone and sorbitol are shown in green.
    Red symbols: established or putative functional targets for PTX3003 drugs. Blue
    arrows: activation links; red lines: inhibition links; dashed lines: functional
    effect link is receptor-type specific.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PENK
  - PDYN
  - FLNA
  - GAL
  - GALP
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - IGF1
  - GAST
  - GALNS
  - PAGR1
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - UMOD
  - EGR2
  - DPYD
  - DPYS
  - PMP22
  - PXMP2
  - TRPV1
  - GATA1
  - SOS1
  - SRC
  - FGR
  - FYN
  - YES1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - FCGR1A
  - FCGR1BP
  - FCGR1CP
  - P2RX3
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - BCL2
  - PTK2
  - baclofen
  - GABA
  - naltrexone
  - naltrexone POYN
  - d-sorbitol
  - Cancer
---
